{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"The maximum tolerated dose is defined as the highest safely tolerated dose, where not more than one patient experienced dose-limiting toxicity (DLT), with the next higher dose level having at least two patients who experienced DLT.","groups":[{"description":"The study will employ the standard \"cohort of three\" design. Patients receive ABI-009 in level I dose - 56 mg/m\\^2, in level II dose - 75 mg/m\\^2, and level III dose - 100 mg/m\\^2, each with defined dose of nivolumab - 240 mg IV 30 min. q 3 weeks.","id":"OG000","title":"Dose Escalation Phase 1"}],"paramType":"NUMBER","populationDescription":"Intention-to-treat population (all participant assigned to the Phase I dose escalation part of the study).","reportingStatus":"POSTED","timeFrame":"Week 6","title":"Maximum Tolerated Dose of ABI-009","type":"PRIMARY","unitOfMeasure":"mg/m^2"}